Printer Friendly

SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL

 SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL
 BOSTON, March 16 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN)


announced today at the Cowen Annual Health Care Conference that it has begun the final phase of clinical testing for its lead product, ANTRIL(TM), for the treatment of sepsis syndrome.
 Sepsis syndrome is the clinical complex of signs and symptoms that result from severe systemic infection. It is estimated that 500,000 people in the United States receive treatment for sepsis syndrome but current therapy is inadequate and more than 100,000 of those patients die as a result. The incidence of the disorder is similar in Europe and other developed countries as well.
 ANTRIL, the company's lead product, is a recombinant version of a naturally occurring protein known as an interleukin-1 receptor antagonist. Interleukin-1 (IL-1) has been shown to be a major mediator of sepsis syndrome. Because ANTRIL blocks the action of IL-1, it is being tested as a new therapy for sepsis syndrome and septic shock. Phase II results, reported in November 1991, demonstrated that ANTRIL produced a dose-related reduction in mortality in patients with sepsis syndrome. The Phase III study, which has just begun, will test the effectiveness of ANTRIL in a large patient population. The clinical trial is an international study which is being conducted in eight countries. The study is expected to be completed by the end of 1992.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein based pharmaceuticals. The company's research is targeted toward products to treat inflammatory diseases, chronic skin ulcers and neurological diseases. Synergen's lead product, ANTRIL, is in clinical testing for sepsis syndrome, rheumatoid arthritis, asthma, inflammatory bowel disease, graft vs. host disease, chronic myelogenous leukemia, and a model of cachexia.
 -0- 3/16/92
 /CONTACT: Debra Catz Bannister of Synergen, 303-938-6242/
 (SYGN) CO: Synergen Inc. ST: Massachusetts, Colorado IN: MTC SU:


MC -- DV003 -- 8290 03/16/92 11:49 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1992
Words:322
Previous Article:SIEMENS/STANADYNE JOIN IN ELECTRONIC DIESEL FUEL INJECTION DEVELOPMENT
Next Article:VIRTUAL REALITY ANNOUNCES REVERSE STOCK SPLIT
Topics:


Related Articles
SYNERGEN AND INSITE VISION ANNOUNCE COOPERATIVE AGREEMENT TO EVALUATE ANTRIL FOR OPHTHALMIC APPLICATIONS
SYNERGEN COMPLETES PHASE III CLINICAL TRIAL ENROLLMENT FOR ANTRIL IN SEPSIS; 900 PATIENTS RECRUITED IN THE U.S., CANADA AND EUROPE
SYNERGEN FILES EUROPEAN MARKETING APPLICATION FOR ANTRIL IN SEVERE SEPSIS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters